Search Results 941-950 of 21652 for Inhibition
Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti- CTLA-4 antibodies, other checkpoint inhibitors. Other protocol ...
Anticholinergic and anti-muscarinic agents, which inhibit GI smooth muscle contraction; Calcium channel inhibitors, which inhibit calcium transport into GI ...
... inhibitors, CDK4/6 inhibitors, TDM-1, pertuzumab, or immunotherapy). (Participants may still be taking adjuvant therapy with trastuzumab or adjuvant ...
... inhibition of proinflammatory cytokine secretion. In pigs, AdhIL-10-treated lungs exhibited attenuated inflammation and improved function after ...
Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors. Known diagnosis of severe dementia. Inability to obtain informed consent ...
... inhibitors," Dr. Dinh says. In the body, an enzyme known as the PARP protein helps repair damaged DNA in cancer cells, allowing them to divide. PARP inhibitors ...
Patients who were treated with letrozole or another aromatase inhibitor for ... Known strong inducers or inhibitors of CYP3A4/5, including grapefruit ...
Patients receiving strong inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4). Use of the following strong or moderate inhibitors are ...
Tyrosine kinase inhibitor therapy. Subjects not having a PBTL p16INK4a ... inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus).
Huperzine A acts as a cholinesterase inhibitor ... The Alzheimer's Association recommends not taking huperzine A, especially if you're taking a prescribed ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.